MedWatch

Genmab enters huge deal with Abbvie - gets DKK 5 billion in the bank

After a long hunt for a partner, Genmab has entered a deal with Abbvie over three antibody drugs, including epcoritamab. The deal has given Genmab an initial DKK 5 billion (USD 750 million) and can give them up to DKK 26 billion in total (USD 3.9 billion).

Genmab didn't just find a partner for its drug candidate epcoritamab on Wednesday - its long hunt has also led to a deal for a further two antibodies.

The company has made a deal with US pharmaceutical group Abbvie, where the two companies will work together on two more of Genmab's potential drug candidates. Abbvie is not just paying loose change to get access to the three development programs.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Trial banner

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier